@FierceMedDev: From FierceDiagnostics: T2 jumps into pivotal trial for Candida assay. Article | Follow @FierceMedDev
@DamianFierce: After 22 years at the helm, AMRI's CEO is stepping down at year's end. Story from FierceCRO | Follow @DamianFierce
@MarkHFierce: J&J is sizing up buyers for its Ortho Clinical Diagnostics unit. Will it go for $5B? More | Follow @MarkHFierce
@MichaelGFierce: ICYMI: Capsugel picks up Bend Research with dispersion delivery tech. Story from FierceDrugDelivery | Follow @MichaelGFierce
> New U.K. research hasn't turned up any evidence that all-metal hip replacements increase the risk of cancer. Story
> Israel's Keystone Heart gained a CE marking for its new TriGuard device, which is designed to help minimize the risk of brain damage during a transcatheter aortic valve replacement procedure. Item
> ICU Medical ($ICUI) won the FDA's 510(k) clearance for its ChemoLock needle-free closed system transfer device, which is designed, in part, to keep clinicians and patients safe from exposure to hazardous drugs. Item
> German researchers are developing a drone that would deliver a defibrillator to a patient suffering a heart attack. Story
> Florida officials are pitching their state as a place that is becoming a hotspot for medical device and other life sciences companies. Story
> Intelomed brought in a $4M Series A-1 round to help back clinical tests and sales efforts for its noninvasive devices and software designed to monitor cardiovascular stability. Item
Biotech News
@FierceBiotech: New Industry Voices: Place your bets--A horse race emerges in the migraine space by Randall Schatzman, CEO of Alder. Article | Follow @FierceBiotech
@JohnCFierce: Another round of biotech IPOs is drawing near. ICYMI Friday | Follow @JohnCFierce
@Ry_McBride: GSK has given itself a dose (or doses) of online collaboration for its sales organization. More from InformationWeek | Follow @Ry_McBride
@EmilyMFierce: Potential Parkinson's-fighting compounds identified. FierceBiotech Research article | Follow @EmilyMFierce
> DRI Capital gains $1.45B in fresh firepower for drug royalty deals. Report
> Biogen fronts $100M to add Isis R&D pact on neurological diseases. Story
> Crowded field of PhIII COPD contenders will compete for blockbuster market. Article
Pharma News
@FiercePharma: Onyx investors sue over $10.4B Amgen buyout, saying too favorable to Amgen. More from Bloomberg | Follow @FiercePharma
@EricPFierce: FDA approval of Abraxane for pancreatic cancer should extend lives for patients and sales for Celgene. ICYMI Friday | Follow @EricPFierce
@CarlyHFierce: GlaxoSmithKline selling two drinks brands to Japan's Suntory. Release | Follow @CarlyHFierce
> Boehringer targets sales reps in new round of French job cuts. Report
> Bayer's Xarelto faces stepped-up reports of side effects, deaths. Story
CRO News
> Novella shuffles execs as Quintiles deal pends. Item
> AMRI chief stepping down at year's end. News
> Patheon posts Banner quarter on 30% sales surge. Article
> Covance teams with Indiana U. for early trials. Story
> Capsugel snaps up Bend with eye on oral formulations. More
Biotech IT News
> GlaxoSmithKline picks up online collaboration tools for medical staffers. Report
> Texas biotech software outfit trumpets open source tools. Item
> Genentech backs development of video game for kids with cancer. More
> In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Story
> Accelrys scoops up Bay Area software firm for $15.3M. Article